Medication adherence and treatment fatigue — branching viva

Stem

The examiner will test whether you can define adherence correctly, measure it without blame, and defend an engagement-first stance under pressure. [1] [2]

Branch 1 — Definition and phases

Examiner: Define medication adherence. Why has "compliance" been retired? [1]

Strong answer: Adherence is the extent to which a person's behaviour in taking medication corresponds to agreed recommendations. Compliance implied obedience to an instruction and blames the patient; adherence frames a shared, negotiated behaviour, which protects disclosure. [1]

Examiner: Split it into phases. [2]

Strong answer: Initiation — whether the medicine is ever started; implementation — whether it is taken as prescribed day to day; persistence — whether it is continued over time. A first-prescription non-starter, an erratic taker, and a two-year stopper each need a different conversation. [2]

Branch 2 — Measurement

Examiner: How do you measure adherence, and why not rely on self-report alone? [5]

Strong answer: Multimodally. Self-report opens the conversation; refill and pharmacy records estimate implementation over time; objective measures — therapeutic drug levels, electronic monitoring, device downloads, biomarkers such as HbA1c — triangulate it. Each captures a different facet and misleads alone, and white-coat adherence can raise a pre-visit level and mask chronic non-adherence. [5]

Branch 3 — Treatment fatigue

Examiner: What is treatment fatigue, and why does escalation of monitoring make it worse? [1]

Strong answer: The cumulative erosion of motivation from years of regimen burden, side-effects and identity load — the dose moved to later, to tomorrow, to a quiet stop. Escalating surveillance confirms the young person's suspicion that the system values the drug level more than them, and accelerates disengagement. The response is re-engagement, not a lecture. [1]

Branch 4 — Intervention

Examiner: Give me a tailored, evidence-based plan for an adolescent struggling with adherence. [3]

Strong answer: Frame non-judgementally with time alone; measure multimodally; map the barrier across patient, regimen, family and system and probe the darkest first; agree shared goals with motivational interviewing, which has meta-analytic support for improving adherence; simplify the regimen with the specialist team where licensed; add reminders and technology for the unintentional component; involve psychology and family-based support for the psychosocial drivers; then re-measure and name the next contact. The outcome is sustained engagement, not perfect doses. [3]

Branch 5 — Transplant non-adherence and transition

Examiner: A 17-year-old transplant recipient nearing transfer to adult care has subtherapeutic tacrolimus and asks you not to tell the team. What do you do? [2]

Strong answer: Lapsed immunosuppression drives rejection and graft loss, so suspected non-adherence needs urgent transplant-team involvement — this is not a confidentiality you can keep at the expense of the graft. Explain what must be shared and why, screen for graft dysfunction and exit to acute care if any is found, and address the transition cliff with a warm handover and strengthened readiness. Build psychological safety so the disclosure keeps coming; never punish it. [2]

Examiner extras

• Lapses are the rule, not the exception — engagement after a lapse is the success case. [1]
• Reframe "non-compliant" as "struggling with adherence"; language shapes disclosure. [1]
• The asymptomatic-on-treatment trap is sharpest in epilepsy; name it and explain why withdrawal risks SUDEP. [4]